Quick Order

SFTPD / SP-D / SFTP4 Antibody, Rabbit PAb, Antigen Affinity Purified

  • SFTPD / SP-D / SFTP4 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
DatasheetReviewsRelated ProductsProtocols
Mouse SFTPD Antibody Product Information
Immunogen:Recombinant Mouse SFTPD protein (Catalog#50205-M08H)
Clone ID:
Ig Type:Rabbit IgG
Concentration:
Endotoxin:
Formulation:0.2 μm filtered solution in PBS
Preparation:Produced in rabbits immunized with purified, recombinant Mouse SFTPD (rM SFTPD; Catalog#50205-M08H; NP_033186.1; Met 1-Phe 374). SFTPD specific IgG was purified by mouse SFTPD affinity chromatography.
Mouse SFTPD Antibody IHC Application Image
SFTPD / SP-D / SFTP4 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
[Click to enlarge image]
Caption:
Immunochemical staining of mouse SFTPD in mouse lung with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
Other SFTPD Antibody Products
Immunochemical staining of human CCNF in human brain with rabbit polyclonal antibody (1 µg/mL, formalin-fixed paraffin embedded sections).
SFTPD/SP-D Background

Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.

Mouse SFTPD/SP-D References
  • Leth-Larsen R, et al. (2005) A common polymorphism in the SFTPD gene influences assembly, function, and concentration of surfactant protein D. J Immunol. 174(3): 1532-8.
  • Moran AP, et al. (2005) Role of surfactant protein D (SP-D) in innate immunity in the gastric mucosa: evidence of interaction with Helicobacter pylori lipopolysaccharide. J Endotoxin Res. 11(6): 357-62.
  • Hartl D, et al. (2006) Surfactant protein D in human lung diseases. Eur J Clin Invest. 36(6): 423-35.
  • Krueger M, et al. (2006) Amino acid variants in Surfactant protein D are not associated with bronchial asthma. Pediatr Allergy Immunol. 17(1): 77-81.
  • Glas J, et al. (2008) Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: potential role as a biomarker. Tissue Antigens. 72(1): 21-8.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"